Vaccines

New recommendations are intended to aid biomedical firms in achieving licensure of a safe and effective vaccine.

While smallpox may not be in headlines today, the illness (treated with tecovirimat) remains a threat.

Dr. Luwy Musey, executive director in biologics, Merck Research Laboratories, discusses what clinicians need to know about the latest PCVs.

In a joint-interview, we discuss the PCV pipeline with Dr. Luwy Musey (of Merck & Co.) and Dr. Steven Pelton.

Patrick Soon-Shiong, MD, Chairman and CEO of ImmunityBio, explains why the firm's COVID-19 research benefits from drawing on a background in cancer.

Data were published using the International Symposium on Pneumococci and Pneumococcal Diseases online digital library.

Infectious disease experts have recommended that stockpiles of several promising vaccine candidates be created as they enter late stage development.

Patrick Soon-Shiong, MD, describes goals and expectations for the accelerated coronavirus vaccine program Operation Warp Speed.

As of June 1, there have been at least 6 cases of Ebola detected in Mbandaka, a port city with a population of more than 1.2 million people.

In all trial participants to date, the vaccine candidate led to seroconversion with binding antibody levels either at or above levels seen in convalescent sera.

Barriers to recommended vaccine coverage for low-income American adults include disparity in Medicaid programs and low reimbursement amounts, a new study found.

What is the hopeful expectation of the new candidates, relative to previously developed vaccines?

Preventive medicine expert William Schaffner, MD, discusses what it will take for investigators to properly assess and manufacture a vaccine.

In a new phase 4 study, investigators found giving patients raxibacumab at the start of anthrax vaccine adsorbed administration does hurt the protective quality of the vaccine.

Moderna hopes to initiate phase 2 and late stage studies of its vaccine candidate, mRNA-1273, against COVID-19.

Flu burden for children can be reduced by improving adherence to a 2-dose series of flu vaccinations.

The attenuated virus in oral polio vaccines has developed the ability to evolve and spread to humans. Now, investigators have developed a new vaccine without the ability to make such changes.

Vaccination rates remain below recommended levels in many areas.

Disparate reimbursement policies disincentivize clinicians from vaccinating adults with lower incomes.

The authors of the review recommend the continued use of MMR vaccines on a mass scale.

Gain more insight on clinical trials evaluating investigational agents for COVID-19.

The differences do not mean that the measles vaccine is ineffective.

In mouse models, the vaccine produced antibodies for SARS-CoV-2 which may offer sufficient protection.

Ian Frank, MD, gives an overview of different HIV vaccine efforts in recent years and on the horizon.

A study has examined the availability of negative vaccine information online.

The 20vPnC pneumococcal conjugate vaccine candidate was found comparable to licensed products in safety and immunogenicity.

Colleen Kelley, MD, MPH, describes the current state of HIV vaccine efforts.

A new study demonstrates that the introduction of a universal immunization program had positive impact on the educational attainment of people in India’s school system.

A study has identified geographic and socioeconomic drivers of conscientious vaccine exemption choice in Texas.

The investigators of a new observational cohort study on incidence of tetanus and diphtheria in 31 countries have provided data that suggest no benefit associated with performing adult booster vaccinations.